Immuno-Biological Lab, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 44% Increase, Highest in Twenty Two Terms

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Feb 18, 2025 3:30 pm JST Revision

4570 Immuno-Biological Laboratories Co., Ltd. 【J-GAAP】

Guidance Update Report

Immuno-Biological Laboratories Co., Ltd. <4570> [TSE Growth] announced a performance revision after the market closed on February 18th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 has been revised upward 50.0%, from the previous forecast of 120 million yen to 180 million yen (compared to 125 million yen in the previous period), reaches new record high for the first time in twenty two terms, turning to a 44.0% increase in the consolidated ordinary profit outlook.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit is expected to increase 2.1 times, from the previous forecast of 56 million yen to 116 million yen (compared to 95 million yen in the same period of the previous year), turning to a 22.1% increase in the consolidated ordinary profit outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	481	52	56	44	4.7	0	Nov 11, 2024	J-GAAP
Oct - Mar, 2024 New	481	112	116	144	15.5	0	Feb 18, 2025	J-GAAP
Revision Rate	0.0%	+115.4%	+107.1%	+227.3%	+226.8%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	925	120	120	115	12.4	0	May 14, 2024	J-GAAP
Mar, 2025 New	925	180	180	215	23.1	0	Feb 18, 2025	J-GAAP
Revision Rate	0.0%	+50.0%	+50.0%	+87.0%	+86.9%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	451	91	95	160	17.3	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	481	112	116	144	15.5	0	Feb 18, 2025	J-GAAP
YoY	+6.7%	+23.1%	+22.1%	-10.0%	-10.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	794	57	-149	-289	-31.1	0	May 12, 2023	J-GAAP
Mar, 2024	816	104	125	186	20.1	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	925	180	180	215	23.1	0	Feb 18, 2025	J-GAAP
YoY	+13.4%	+73.1%	+44.0%	+15.6%	+15.1%